Even though the breadth of what science hopes to deliver is still a work in progress, strong potential and early success have made a major portion of the regenerative medicine and therapy market very attractive to investors. Manufacturers are working to produce solutions that target a variety of diseases, including some of the most notorious conditions such as cancer, stroke, brain disorders, heart disease, and diabetes. Additionally, work continues on one of the industry’s more elusive endeavors: creating functioning, autonomous body organs to be implanted into patients. The progress that has been made thus far lies mainly at the feet of the scientific community, much of it in the academic setting, but a significant amount work is also coming from start-up and young companies that are closer to making these therapies mainstream.
The regenerative market is generally divided into three categories: cell therapy, tissue engineering and biomaterials, and gene and gene-modified cell therapies and genome editing. Manufacturers in these areas are building products that fall into the drug and device spaces, and pharmaceutical companies clearly outnumber device companies; however, the nature of the technology allows for both industries to compete and/or work with each other
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?